Part Two: Major Clinical Trials

Contents:

• Trials for Stroke Prevention in Atrial Fibrillation
• Trials for Primary Stroke Prevention in Atrial Fibrillation
• Risk Factors for Stroke and Efficacy of Antithrombotic Therapy in Atrial Fibrillation
• Methods
• Baseline Characteristics of Patients
• Quote from Investigators
• Efficacy of Warafin
• Quote from Investigators
• Patients Assigned to Warafin in ATF Trials
• Major Bleeding Events - Annual Frequency
• Predicting Stroke Risk in AF - Who Benefits Most?
• Annual Events per Age Group
• Stroke Prevention with Warfarin
• SPAF II: Trial Design
• SPAF II Results
• Intracranial Hemorrhage in AF Trials
• Patients Assigned to Warfarin in AF Trials
• European Atrial Fibrillation Trial: Design
• European Atrial Fibrillation Trial Results
• Efficacy of Aspirin Compared with Control
• SPAF III Study
• SPAF III Results

 

Part One: Pathophysiology and Clinical Manifestations

Part Three: Guidelines & Treatment Approaches